```
Page 210
             UNITED STATES PATENT AND TRADEMARK OFFICE
 1
 2
             BEFORE THE PATENT TRIAL AND APPEAL BOARD
 3
 4
     MODERNA THERAPEUTICS, INC.,
                                    ) Case No. IPR2018-00680
 5
                                    ) Case No. IPR2018-00739
                 Petitioner,
                                    ) Patent No. 9,404,127
                                    ) Patent No. 9,364,435
 6
     v.
 7
     PROTIVA BIOTHERAPEUTICS,
     INC.,
 8
                 Patent Owner.
 9
                 DEPOSITION UPON ORAL EXAMINATION
10
11
                                 OF
12
                DAVID H. THOMPSON, PhD - VOLUME II
13
14
15
               Taken at 701 Fifth Avenue, Suite 5100
16
                         Seattle, Washington
17
                  DATE TAKEN: February 5, 2019
18
19
20
21
22
23
24
     REPORTED BY: KATHLEEN HAMILTON, RPR, CRR, CCR 1917
     JOB NO: 154633
25
```



```
Page 211
 1
                       APPEARANCES
 2
 3
     FOR THE PETITIONER:
 4
                           MACLAIN WELLS, ESQ.
                           Irell & Manella
                           1800 Avenue of the Stars
 5
                           Los Angeles, CA 90067
 6
 7
 8
 9
     FOR THE PATENT OWNER:
10
                           MICHAEL ROSATO, ESQ.
                           SONJA GERRARD, ESQ.
11
                           Wilson Sonsini Goodrich & Rosati
                           701 Fifth Avenue
12
                           Seattle, WA 98104
13
14
15
16
     ALSO PRESENT:
17
                           ANDREW JANOFF, PhD
18
19
20
21
22
23
24
25
```



		1	Page 212
1		DEPOSITION OF DAVID H. THOMPSON, PhD	
2		EXAMINATION INDEX	
3	EXAMINATION E	ЗҮ	PAGE
4	MR. WELLS		213
5	MR. ROSATO		403
6			
7			
8			
9		EXHIBIT INDEX	
10	EXHIBITS FOR	IDENTIFICATION	PAGE
11	Exhibit 10	United States Patent Application Publication US 2006/0240554 A1	214
12	Exhibit 11	Three-Dimensional Imaging of Lipid	229
13		Gene-Carriers: Membrane Charge Density Controls Universal Transfection Behavior in Lamellar Cationic Liposome-DNA	
14	Exhibit 12	Complexes New multivalent cationic lipids reveal	240
15	EXIIDIC IZ	bell curve for transfection efficiency versus membrane charge density: Lipid-DNA	210
16	Exhibit 13	complexes for gene delivery United States Patent Application	294
17		Publication US 2007/0042031 A1	
18	Exhibit 14 Exhibit 15	United States Patent No. 8,058,069 B2 Rational design of cationic lipids for siRNA delivery	304 373
19	Exhibit 16	Liposome Drug Products Chemistry, Manufacturing, and Controls; Human	379
20		Pharmacokinetics and Bioavailability; and Labeling Documentation Guidance for	
21		Industry	
22	Exhibit 17	Diffusible-PEG-Lipid Stabilized Plasmid Lipid Particles	384
23	Exhibit 18 Exhibit 19	United States Patent No. 8,236,943 B2 United States Patent Application	388 397
	EXIIIDIC 13	Publication US 2013/0116307 A1	391
24			
25			



- DAVID H. THOMPSON, PhD
- 2 SEATTLE, WASHINGTON; FEBRUARY 5, 2019
- 3 8:54?a.m.
- 4 -000-

5

- 6 EXAMINATION
- 7 BY MR. WELLS:
- 8 Q. You understand that you're still under oath that
- 9 you gave yesterday to tell the truth and the whole
- 10 truth?
- 11 A. Yes.
- 12 Q. And during the breaks yesterday or yesterday
- 13 evening, did you discuss your deposition testimony here
- 14 today with anybody?
- 15 A. No.
- Q. With regard to the `435 patent, do you
- 17 understand that one of the grounds involves the 054
- 18 reference? Do you recall that?
- 19 MR. ROSATO: Objection. Form.
- THE WITNESS: 054?
- 21 BY MR. WELLS:
- Q. Oh, actually I should have said `554. I
- 23 apologize. That was my error. Let's try that again.
- 24 A. Yeah.
- Q. With regard to the `435 patent, do you recall



- DAVID H. THOMPSON, PhD
- 2 one of the references cited was the `554 patent?
- 3 A. Correct. Yes, I recall.
- 4 Q. Okay. And I'll give you a copy of the `554
- 5 patent should you need it. It was previously marked as
- 6 Exhibit 1004 to the `435 IPR.
- 7 (Exhibit 10 marked.)
- 8 BY MR. WELLS:
- 9 Q. Now, the `554 publication has a formulation
- 10 called the LO54 formulation. Do you recall that?
- 11 A. Yes, I do recall.
- 12 Q. And the cationic lipid used in the LO54 lipid
- 13 mixture is a DMOBA, do you recall that?
- 14 A. I recall the structure. I don't... The acronym
- 15 I would have to look back and refamiliarize myself, but
- 16 it's a -- an aerial ether dimethylamino -- benzyl
- 17 dimethylamino lipid.
- 18 Q. And if you look at paragraph 122 of your `435
- 19 declaration, that has a discussion where you identify
- 20 DMOBA as the acronym.
- 21 A. Paragraph...?
- 22 0. 122.
- 23 A. 122. Yes; okay I see it.
- 24 O. And do you know whether DMOBA is an ionizable
- 25 cationic lipid?



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

